Evidence map›Paper›PMID 40421510›Full record

ArticleEuropean journal of breast health2025

Breast Myofibroblastoma: A Single Institutional Case Series.

Meghna Pinnaka, Melissa Garcia Patino, Vasupriya Ravi, Alia Nazarullah, Ismail Jatoi

Abstract read
In one paragraph

Article in European journal of breast health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meghna PinnakaDepartment of Pathology, UT Health San Antonio Long School of Medicine, San Antonio, Texas, USA.ORCID 0009-0002-4103-0831
Melissa Garcia PatinoDepartment of Pathology, UT Health San Antonio Long School of Medicine, San Antonio, Texas, USA.ORCID 0000-0003-0921-0533
Vasupriya RaviDepartment of Surgical Oncology and Endocrine Surgery, University of Texas Health Science Center, San Antonio, Texas, USA.ORCID 0009-0006-2063-6235
Alia NazarullahDepartment of Pathology, UT Health San Antonio Long School of Medicine, San Antonio, Texas, USA.ORCID 0000-0001-7954-6740
Ismail JatoiDepartment of Surgical Oncology and Endocrine Surgery, University of Texas Health Science Center, San Antonio, Texas, USA.ORCID 0000-0002-6775-0039

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Breast myofibroblastoma (BM) is a rare, benign mesenchymal tumor primarily affecting older men and postmenopausal women. This study analyzed the clinicopathologic features, immunohistochemical profiles, and treatment outcomes of five BM cases diagnosed at a single institution over a period of 20 years. Materials and Methods: A retrospective review was conducted for five patients diagnosed with BM between 1998 and 2024. Data included age, clinical presentation, tumor size, histopathologic findings, immunohistochemical profiles, treatment approaches, and follow-up outcomes. Results: The median age at diagnosis was 68 years, with a mean tumor size of 5.06 cm. Clinical presentation included palpable, painless masses in two patients and an incidental finding in one, while data were unavailable for two cases. Histopathology showed well-circumscribed, unencapsulated tumors composed of spindle cells with admixed adipose tissue and collagen bundles. Immunohistochemically, all tumors were positive for desmin and CD34, with variable smooth muscle actin expression and negative S100 staining. No cases exhibited nuclear beta-catenin staining or 13q14 deletions. All patients underwent surgical excision, with one requiring re-excision due to tumor abutting margins. No recurrences were observed during follow-up (2-18 months). Conclusion: BM is a benign tumor with favorable outcomes following surgical excision. This study underscores the variability in immunohistochemical staining and the importance of distinguishing BM from other spindle cell tumors. Increased numbers of published cases and refining diagnostic markers may be important to improve clinical management and reduce diagnostic uncertainty.

Indexed as

BreastmyofibroblastomaRB1 deletionspindle cell tumor

Identifiers

PMID40421510
PMCPMC12180106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.